PD-L1 expression correlates with response to immunotherapy in certain tumor types, and neutralization of GDF-15 activity could be a possible treatment to extend the benefits of immunotherapy in patients with solid cancers and metastases [25,28]. Here, GDF15 is linked to neoplasm.